HIGHLIGHTS
- who: Admin from the Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) et Institut du Cancer de , Department of Medicine, Université de Montréal, Montréal, QC H C , Canada have published the research work: C/EBP‐‐Mediated Transcription of Rad51 in Castrate‐Resistant Prostate Cancer, in the Journal: (JOURNAL)
- what: The authors show that Amlexanox combined with Olaparib decreased CRPC cell proliferation and enhanced DNA damage. The authors showed that Amlexanox blocks the Rad51 recruitment induced by Olaparib and inhibits Rad51 transcription mediated by C/EBP‐, rendering cells more . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.